Matthew Zvan

ParaPRO LLC in its US$89.5 million asset sale to Cipher Pharmaceuticals

On July 29, 2024, Cipher Pharmaceuticals Inc. announced the signing of a definitive asset purchase agreement with ParaPRO LLC ("ParaPRO") and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total...

Lead Office: Toronto Date Announced: Jul 29, 2024 Value: US$ 89.5 million

Kyndryl in the sale of its Securities Industry Services business to Broadridge

On May 13, 2024, Kyndryl announced the proposed sale by Kyndryl Canada of its Canadian Securities Industry Services, wealth and capital markets technology platform to Broadridge Financial Solutions. In connection with the sale, Kyndryl plans to offer managed services and capabilities to Broadridge...

Lead Office: Toronto Date Announced: May 13, 2024 Value: -

Fusion Pharmaceuticals in its acquisition by AstraZeneca

On March 19, 2024, Fusion Pharmaceuticals announced that it entered into a definitive agreement to be acquired by AstraZeneca for a transaction value of approximately US$2.4 billion. Through this acquisition, AstraZeneca is taking a significant leap towards its goal of revolutionizing cancer...

Lead Office: Toronto Date Closed: -- Value: US$2.4 billion